Article
作者: Stebbins, Aaron W. ; Yang, Nianxin ; Paddock, Marcia N. ; Patel, Chirag H. ; Lee, James J. ; Hendrickson, David ; Godfrey, Patrick M. ; Fong, Nicole ; Nguyen, Tuan Andrew ; Malahias, Evangelia ; Kong, Wenjun ; Powell, Jonathan D. ; Hake, Kayley ; Brown, Jordan ; Wang, Jiaxi ; Gupta, Shagun ; Penland, Lolita ; Sun, Im-Meng ; Balibalos, John ; Kharbanda, Samir ; Harding, Fiona A. ; Liu, Yue ; O’Hara, Jacqueline ; Li, Ka Man ; Tai, Po-Han ; Chan, Leanne J.G. ; McAllister, Fiona E. ; Shahryari, Varahram ; Creixell, Marc ; Finn, Kenneth J.
Abstract:Metastasis remains the leading cause of cancer mortality, yet effective therapies for inhibiting and treating metastasis are limited. Therapeutic responses are influenced by organ-specific immune microenvironments, highlighting the need to develop strategies to pharmacologically modulate these niches. In this study, using the clinical-stage inhibitor ABBV-CLS-484 (AC484) as a chemical probe, we demonstrated that systemic PTPN1/2 inhibition remodels the pulmonary myeloid landscape, specifically activating alveolar macrophages (AMs) toward a tumoricidal state. Integrated single-cell and spatial transcriptomics and functional assays revealed that AC484 promotes accumulation, interferon γ (IFNγ) production and responsiveness, and tumor-killing activity of AMs within metastatic lesions. Depletion of AMs diminished the antimetastatic efficacy of AC484. Mechanistically, inhibition of PTPN1/2 amplified IFNγ–STAT1 signaling in AMs, and disrupting this pathway impaired the tumor control capability of AC484. These findings delineate a distinct innate immune axis where PTPN1/2 acts as a molecular “brake” on AM activation, suggesting that pharmacologically unleashing tissue-resident macrophages offers a therapeutic strategy to overcome metastatic progression, particularly in microenvironments in which adaptive immunity is insufficient.
Significance::Alveolar macrophages are potent anti-metastatic immune effectors that can be targeted with pharmacological PTPN1/2 inhibitors to amplify IFNγ-STAT1 signaling and tumoricidal activity, establishing a strategy to reactivate tissue-resident immunity against metastasis.